HTML Microdata document

This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n5	http://linked.opendata.cz/resource/mesh/concept/
rdfs	http://www.w3.org/2000/01/rdf-schema#
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n4	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: nci:C2228
rdf:type: owl:Class
rdfs:label: Apolizumab
owl:equivalentClass: _:vb629674
nci:A7: nci:C16692
nci:A8: nci:C63923
nci:P106: Immunologic Factor Amino Acid, Peptide, or Protein
nci:P108: Apolizumab
nci:P175: 704867 710066
nci:P207: C1122758
nci:P210: 267227-08-7
nci:P303: Recurrent Hodgkins Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; B-cell Lymphoproliferative Disorders; Recurrent Non-Hodgkins Lymphoma.
nci:P319: G88KCP51RE
nci:P322: FDA
nci:P325: <n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A substance being studied in the treatment of hematologic (blood) cancers. Apolizumab binds to a protein called ID10, which is found on the surface of some types of immune cells and cancer cells. It may help the immune system kill cancer cells. It is a type of monoclonal antibody.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329: 38451
nci:P330: 38451
nci:P366: Apolizumab
nci:P90: <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>apolizumab</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000045051</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>MoAb Hu1D10</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>1D10 Anti-lymphoma Antibody</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>APOLIZUMAB</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>G88KCP51RE</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>MoAb: Hu1D10</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0710066</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Apolizumab</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Monoclonal Antibody Hu1D10</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Remitogen</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Monoclonal antibody 1D10</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97: <n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code: C2228
n4:hasConcept: n5:M0416750

Subject Item: _:vb629674
rdf:type: owl:Class
owl:intersectionOf: _:vb733649

Subject Item: _:vb646423
rdf:type: owl:Restriction
owl:onProperty: nci:R72
owl:someValuesFrom: nci:C12474

Subject Item: _:vb646424
rdf:type: owl:Restriction
owl:onProperty: nci:R146
owl:someValuesFrom: nci:C16692

Subject Item: _:vb646425
rdf:type: owl:Restriction
owl:onProperty: nci:R124
owl:someValuesFrom: nci:C40474

Subject Item: _:vb646426
rdf:type: owl:Restriction
owl:onProperty: nci:R125
owl:someValuesFrom: nci:C16298

Subject Item: _:vb646427
rdf:type: owl:Restriction
owl:onProperty: nci:R125
owl:someValuesFrom: nci:C41572

Subject Item: _:vb646428
rdf:type: owl:Restriction
owl:onProperty: nci:R125
owl:someValuesFrom: nci:C20150

Subject Item: _:vb733649
rdf:first: nci:C20401
rdf:rest: _:vb748547

Subject Item: _:vb748547
rdf:first: _:vb646423
rdf:rest: _:vb748548

Subject Item: _:vb748548
rdf:first: _:vb646424
rdf:rest: _:vb748549

Subject Item: _:vb748549
rdf:first: _:vb646425
rdf:rest: _:vb748550

Subject Item: _:vb748550
rdf:first: _:vb646426
rdf:rest: _:vb748551

Subject Item: _:vb748551
rdf:first: _:vb646427
rdf:rest: _:vb748552

Subject Item: _:vb748552
rdf:first: _:vb646428
rdf:rest: rdf:nil